Aclarion, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ACON | TEM | BRTX | TNON | SCNX | ICCM | |
|---|---|---|---|---|---|---|
| Market cap | 6.47M | 12.27B | 2.42M | 8.01M | 6.42M | 5.01M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.4 | -1,190.7 | -0.2 | -0.2 | — | -0.3 |
| Price/book | 0.3 | 27.5 | 0.7 | -0.2 | 0.1 | 0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −74.92% | −24.92% | −94.03% | −91.30% | −79.11% | −95.66% |
| Today | −4.06% | −4.14% | −6.42% | −12.61% | +3.99% | −1.82% |
The closest companies by business and industry (Health Information Services). Prices may be delayed up to 15 min.
Latest news
All ACON news ›Price to book forward of Aclarion, Inc. – NASDAQ:ACONW
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in…
Contrasting Veeva Systems (NYSE:VEEV) & Aclarion (NASDAQ:ACON)
Posted by Sarita Garza on Oct 4th, 2026 Aclarion (NASDAQ:ACON – Get Free Report) and Veeva Systems (NYSE:VEEV – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on…
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research CLARITY is a prospective, randomized clinical trial…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
themarketsdaily.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.